podis-shutterstock-com-biologics-
PODIS / Shutterstock.com
8 September 2016AsiaAlan Adcock and Atthachai Homhuan

A bright future for biologics in Thailand

In 2002, the Thai government initiated a universal scheme to bring equitable healthcare access to the general public. Under the scheme, hospitals receive per capita funding based on 47 million people. At the outset, funding was approximately $38 per person; now, it is $83. Although per capita funding has more than doubled, the current figure is still low. This budget constraint has led the Thai government to favour generic companies as opposed to originator companies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
31 March 2026   The clash between one of India’s largest B2B marketplaces and the country’s drugs regulator challenges the “passive” position of such platforms with regards to allegedly unlawful pharmaceutical listings, says Aarti Aggarwal of Remfry & Sagar.
Asia
20 March 2026   As the patent protecting semaglutide—the drug that made Novo Nordisk one of Europe's most valuable companies—expires in ten countries, the pressure mounts for prices and market leaders alike.
Asia
5 February 2026   The British-Swedish pharma giant pays $1.2 billion upfront for access to next-generation weight-loss treatment as China patent cliff changes the market.